CY1118676T1 - Βελτιωμενη συνθεση ανασυσταμενου επιφανειοδραστικου η οποια περιεχει αναλογα της επιφανειοδραστικης πρωτεϊνης β (sp-b) και της επιφανειοδραστικης πρωτεϊνης c (sp-c) - Google Patents

Βελτιωμενη συνθεση ανασυσταμενου επιφανειοδραστικου η οποια περιεχει αναλογα της επιφανειοδραστικης πρωτεϊνης β (sp-b) και της επιφανειοδραστικης πρωτεϊνης c (sp-c)

Info

Publication number
CY1118676T1
CY1118676T1 CY20171100262T CY171100262T CY1118676T1 CY 1118676 T1 CY1118676 T1 CY 1118676T1 CY 20171100262 T CY20171100262 T CY 20171100262T CY 171100262 T CY171100262 T CY 171100262T CY 1118676 T1 CY1118676 T1 CY 1118676T1
Authority
CY
Cyprus
Prior art keywords
proposal
cycle
recommended
improved composition
protein
Prior art date
Application number
CY20171100262T
Other languages
English (en)
Inventor
Fausto Pivetti
Monica Bocchi
Raschini Annamaria Soliani
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41055357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118676(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of CY1118676T1 publication Critical patent/CY1118676T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0082—Lung surfactant, artificial mucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides

Abstract

Η παρούσα εφεύρεση αφορά ένα ανασυσταμένο πνευμονικό επιφανειοδραστικό, το οποίο περιλαμβάνει έναν φορέα λιπιδίου, έναν συνδυασμό αναλόγου πολυπεπτιδίου της φυσικής επιφανειοδραστικής πρωτεΐνης SP-C με ένα συγκεκριμένο ανάλογο πολυπεπτιδίου της φυσικής επιφανειοδραστικής πρωτεΐνης SP-B. Η εφεύρεση αφορά επίσης φαρμακευτικές συνθέσεις αυτού και τη χρήση αυτού για την αγωγή ή την προφύλαξη έναντι ΣΑΔ και άλλων αναπνευστικών παθήσεων.
CY20171100262T 2009-06-05 2017-02-24 Βελτιωμενη συνθεση ανασυσταμενου επιφανειοδραστικου η οποια περιεχει αναλογα της επιφανειοδραστικης πρωτεϊνης β (sp-b) και της επιφανειοδραστικης πρωτεϊνης c (sp-c) CY1118676T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09162052 2009-06-05
EP10724708.2A EP2438086B1 (en) 2009-06-05 2010-05-31 Improved reconstituted surfactant composition containing analogs of surfactant protein b (sp-b) and surfactant protein c (sp-c)
PCT/EP2010/003293 WO2010139442A1 (en) 2009-06-05 2010-05-31 Improved reconstituted surfactant composition containing analogs of surfactant protein b (sp-b) and surfactant protein c (sp-c)

Publications (1)

Publication Number Publication Date
CY1118676T1 true CY1118676T1 (el) 2017-07-12

Family

ID=41055357

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100262T CY1118676T1 (el) 2009-06-05 2017-02-24 Βελτιωμενη συνθεση ανασυσταμενου επιφανειοδραστικου η οποια περιεχει αναλογα της επιφανειοδραστικης πρωτεϊνης β (sp-b) και της επιφανειοδραστικης πρωτεϊνης c (sp-c)

Country Status (36)

Country Link
US (1) US8399406B2 (el)
EP (1) EP2438086B1 (el)
JP (1) JP5666569B2 (el)
KR (1) KR101668137B1 (el)
CN (1) CN102459327B (el)
AR (1) AR076973A1 (el)
AU (1) AU2010256066B2 (el)
BR (1) BRPI1010120B1 (el)
CA (1) CA2764454C (el)
CL (1) CL2011003003A1 (el)
CO (1) CO6470858A2 (el)
CY (1) CY1118676T1 (el)
DK (1) DK2438086T3 (el)
EA (1) EA021163B1 (el)
ES (1) ES2621974T3 (el)
GE (1) GEP20135967B (el)
HK (1) HK1166332A1 (el)
HR (1) HRP20170445T1 (el)
HU (1) HUE034053T2 (el)
IL (1) IL216718A (el)
JO (1) JO3226B1 (el)
LT (1) LT2438086T (el)
MA (1) MA33374B1 (el)
ME (1) ME01279B (el)
MX (1) MX2011012951A (el)
MY (1) MY159464A (el)
NZ (1) NZ596848A (el)
PE (1) PE20120541A1 (el)
PL (1) PL2438086T3 (el)
PT (1) PT2438086T (el)
SG (1) SG176305A1 (el)
SI (1) SI2438086T1 (el)
TN (1) TN2011000558A1 (el)
TW (1) TWI457132B (el)
UA (1) UA103526C2 (el)
WO (1) WO2010139442A1 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968786B2 (en) 2007-06-22 2015-03-03 Board Of Regents, The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
JP2014514275A (ja) * 2011-03-10 2014-06-19 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム タンパク質ナノ粒子分散系
US9815869B2 (en) 2012-02-09 2017-11-14 University Of Rochester SP-B and SP-C peptides, synthetic lung surfactants, and use thereof
CA2891933C (en) 2012-11-21 2022-07-05 Chiesi Farmaceutici S.P.A. Recombinant pulmonary surfactants comprising sp-b and sp-c analogues and a phospholipid mixture
CN104382942A (zh) * 2014-11-05 2015-03-04 烟台东诚药业集团股份有限公司 一种猪肺表面活性物质混悬液制备新工艺
EP3106090A1 (en) 2015-06-15 2016-12-21 CHIESI FARMACEUTICI S.p.A. System for effective breath-synchronized delivery of medicament to the lungs
EP3285645B1 (en) 2015-04-22 2020-08-12 Chiesi Farmaceutici S.p.A. System for effective breath-synchronized delivery of medicament to the lungs
US11311691B2 (en) 2015-04-28 2022-04-26 Chiesi Farmaceutici S.P.A Device for facilitating the administration of a medicament to the lung by a catheter
CA3016810C (en) * 2016-03-07 2024-04-02 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for administering ppar.gamma. agonists, surfactant peptides and phospholipids
MA45772A (fr) 2016-07-28 2021-04-28 Chiesi Farm Spa Procédé et système d'administration d'un médicament sous forme d'aérosol
MX2019001854A (es) 2016-08-24 2019-11-11 Chiesi Farm Spa Formulacion farmaceutica estable que comprende una composicion de tensioactivo pulmonar reconstituido.
BR112019008169A2 (pt) 2016-10-26 2019-07-09 Chiesi Farm Spa dispositivo para facilitar o posicionamento de um cateter, sistema para entrega de um medicamento em aerossol por meio de um cateter, método para utilização de um dispositivo e kit
PL3558376T3 (pl) 2016-12-22 2022-02-14 Chiesi Farmaceutici S.P.A. Kombinacja terapeutyczna zawierająca surfaktant płucny i steroid do leczenia rozwijającej się BPD
WO2019115771A1 (en) 2017-12-15 2019-06-20 Pari Pharma Gmbh Nebuliser system, holding system, combination comprising nebuliser system and holding system, and aerosol administration method
TW201927286A (zh) 2017-12-15 2019-07-16 義大利商凱西製藥公司 用於噴霧投藥之包含肺表面張力素的藥學調配物
MX2020011127A (es) 2018-04-23 2021-01-15 Chiesi Farm Spa Combinacion terapeutica que comprende agente tensioactivo pulmonar y esteroide para la profilaxis de displasia broncopulmonar (bpd).
EP3666316A1 (en) 2018-12-14 2020-06-17 PARI Pharma GmbH Aerosol delivery device and method of operating the aerosol delivery device
EP3666315A1 (en) 2018-12-14 2020-06-17 PARI Pharma GmbH Aerosol delivery device and method of operating the aerosol delivery device
EP3843105A1 (en) 2019-12-23 2021-06-30 PARI Pharma GmbH Control device for aerosol nebulizer system
EP4097128A1 (en) 2020-01-28 2022-12-07 Chiesi Farmaceutici S.p.A. Polypeptides having improved properties
AU2022306466A1 (en) 2021-07-05 2024-02-15 Chiesi Farmaceutici S.P.A. Process for the preparation of a pulmonary surfactant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2372558A1 (en) 1999-06-11 2000-12-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c)
ITMI20021058A1 (it) * 2002-05-17 2003-11-17 Chiesi Farma Spa Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito
EP1481665A1 (en) * 2003-05-30 2004-12-01 CHIESI FARMACEUTICI S.p.A. Novel lipid mixtures for synthetic surfactants
CN101171514B (zh) * 2005-05-11 2011-07-20 雅玛山酱油株式会社 肺表面活性蛋白的稳定化方法
WO2008011559A2 (en) 2006-07-20 2008-01-24 University Of Rochester Synthetic lung surfactant and use thereof
UA94477C2 (ru) * 2006-10-13 2011-05-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Воспроизведенные сурфактанты, которые имеют улучшенные свойства
EP1997502A1 (en) * 2007-06-01 2008-12-03 CHIESI FARMACEUTICI S.p.A. Reconstituted surfactants having improved properties

Also Published As

Publication number Publication date
WO2010139442A1 (en) 2010-12-09
KR20120028892A (ko) 2012-03-23
MA33374B1 (fr) 2012-06-01
PT2438086T (pt) 2017-04-18
HUE034053T2 (en) 2018-01-29
EP2438086A1 (en) 2012-04-11
CA2764454A1 (en) 2010-12-09
CN102459327B (zh) 2015-06-03
US20110003733A1 (en) 2011-01-06
EP2438086B1 (en) 2017-01-11
TN2011000558A1 (en) 2013-05-24
BRPI1010120A2 (pt) 2019-03-26
MX2011012951A (es) 2011-12-16
CN102459327A (zh) 2012-05-16
US8399406B2 (en) 2013-03-19
UA103526C2 (ru) 2013-10-25
KR101668137B1 (ko) 2016-10-20
JO3226B1 (ar) 2018-03-08
TWI457132B (zh) 2014-10-21
AU2010256066B2 (en) 2015-11-26
ME01279B (me) 2013-06-20
NZ596848A (en) 2013-06-28
SI2438086T1 (sl) 2017-05-31
IL216718A (en) 2016-08-31
PL2438086T3 (pl) 2017-07-31
LT2438086T (lt) 2017-04-10
CO6470858A2 (es) 2012-06-29
EA021163B1 (ru) 2015-04-30
DK2438086T3 (en) 2017-04-10
AR076973A1 (es) 2011-07-20
SG176305A1 (en) 2012-01-30
HRP20170445T1 (hr) 2017-05-19
BRPI1010120B1 (pt) 2022-12-06
ES2621974T3 (es) 2017-07-05
GEP20135967B (en) 2013-11-11
HK1166332A1 (en) 2012-10-26
EA201190292A1 (ru) 2012-06-29
CL2011003003A1 (es) 2012-05-18
AU2010256066A1 (en) 2012-01-12
JP5666569B2 (ja) 2015-02-12
IL216718A0 (en) 2012-02-29
TW201102083A (en) 2011-01-16
PE20120541A1 (es) 2012-05-12
CA2764454C (en) 2018-06-12
JP2012528810A (ja) 2012-11-15
MY159464A (en) 2017-01-13

Similar Documents

Publication Publication Date Title
CY1118676T1 (el) Βελτιωμενη συνθεση ανασυσταμενου επιφανειοδραστικου η οποια περιεχει αναλογα της επιφανειοδραστικης πρωτεϊνης β (sp-b) και της επιφανειοδραστικης πρωτεϊνης c (sp-c)
CY1114716T1 (el) Ανασυσταθεντα επιφανειοδραστικα τα οποια διαθετουν βελτιωμενες ιδιοτητες
CY1120673T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
CY1119265T1 (el) Κατασκευες νανοσωματων τρισθενους αντι ανθρωπινου αναπνευστικου συγκυτιακου ιου (hrsv) για την προληψη και/ή θεραπεια λοιμωξεων της αναπνευστικης οδου
CY1119433T1 (el) Αμινο-υποκατεστημενες ιμιδαζοπυριδαζινες
CY1118691T1 (el) Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
ECSP14030742A (es) Proteínas del factor 21 de crecimiento del fibroblasto
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
CY1119667T1 (el) Υποκατεστημενες ιμιδαζοπυριδαζινες
GT201400111A (es) Triazolopiridinas sustituidas
AR081809A1 (es) Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas
PE20160878A1 (es) Polipeptidos ciclicos para el tratamiento de la insuficiencia cardiaca
CY1123997T1 (el) Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου
AR093569A1 (es) Tensioactivos pulmonares reconstituidos
CY1113726T1 (el) Χρηση της πασιρεοτιδης για την αντιμετωπιση της ενδογενους υπερινσουλιναιμικης υπογλυκαιμιας
BR112017014580A8 (pt) Método para obter um isolado peptídico a partir de uma biomassa de microalgas enriquecidas com proteína
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
EA201790415A1 (ru) ЛИОФИЛИЗИРОВАННЫЕ СОСТАВЫ ДЛЯ АНТИДОТА ФАКТОРА Xa
CL2020000597A1 (es) Métodos y composiciones para tratar enfermedades pulmonares crónicas.
BRPI0813619A2 (pt) peptídeos surfactantes pulmonares sintéticos
AR109799A1 (es) Composición para el tratamiento del cabello
EA202191403A1 (ru) Композиция с высокой концентрацией белка
RS20170169A1 (sr) Poboljšana rekonstituisana kompozicija sufraktanta koja sadrži analoge sufraktanta proteina b (sp-b) i surfaktanta proteina c (sp-c)